


Amendments to the Claims:

Following is a complete listing of the claims pending in the application, as amended:

1. (Currently Amended) A liposome composition, comprising:
a lipid having the formula



where each of R^1 and R^2 is an alkyl or alkenyl chain having between 8-24 carbon atoms, and each of R^1 and R^2 are independently selected;

$n = 0-20$, preferably $n = 1-20$;

L is selected from the group consisting of (i) $-X-(C=O)-Y-$, (ii) $-X-(C=O)-$, and (iii) $-X-$, where X and Y are independently selected from oxygen, NH and a direct bond;

Z is a weakly basic moiety that has a pK of less than 7.4 and greater than about 4.0 and,

a nucleic acid encoding for Factor VIII.

2. (Original) The composition of claim 1, wherein X is NH and Y is oxygen.
3. (Original) The composition of claim 1, wherein L is a carbamate linkage, an ester linkage or a carbonate linkage.
4. (Original) The composition of claim 1, wherein L is $NH-(C=O)-O-$.
5. (Original) The composition of claim 1, wherein Z is an imidazole.
6. (Original) The composition of claim 1, comprising between 1-80 mole percent of the lipid.

7. (Original) The composition of claim 1, wherein Z is a moiety having a pK value between 5.0-6.5.

8. (Original) The composition of claim 1, wherein each of R¹ and R² is an unbranched alkyl or alkenyl chain having between 8-24 carbon atoms.

9. (Original) The composition of claim 8, wherein each of R¹ and R² is C₁₇H₃₅.

10. (Original) The composition of claim 1, wherein n is between 1-10.

11-13. Cancelled

14. (Original) The composition of claim 1, further including a ligand for targeting the liposomes to a target site.

15. (Original) The composition of claim 14, wherein the ligand is one having binding affinity for endothelial tumor cells and which is internalized by such cells.


16. (Original) The composition of claim 15, wherein the ligand is selected from the group consisting of E-selectin, Her-2 and FGF.

17. (Original) The composition of claim 1, wherein said liposomes further include between 5-20 mole percent of a vesicle-forming lipid derivatized with a hydrophilic polymer chain.

18. (Original) The composition of claim 17, wherein said hydrophilic polymer chain is polyethyleneglycol.

19-29. Cancelled

30. (Currently amended) A method for delivery of a therapeutic agent to the cytoplasm of a cell, comprising
preparing liposomes comprising (i) a lipid having the formula



where each of R^1 and R^2 is an alkyl or alkenyl chain having between 8-24 carbon atoms, and each of R^1 and R^2 are independently selected;

$n = 0-20$, preferably $n = 1-20$;

L is selected from the group consisting of (i) $-\text{X}-(\text{C}=\text{O})-\text{Y}-$, (ii) $-\text{X}-(\text{C}=\text{O})-$, and (iii) $-\text{X}-$, where X and Y are independently selected from oxygen, NH and a direct bond;

Z is a weakly basic moiety that has a pK of less than 7.4 and greater than about 4.0 and (ii) a nucleic acid encoding for Factor VIII; and
administering the liposomes to a subject.

31-33. Cancelled

34. (New) The method of claim 31, wherein said preparing includes preparing liposomes comprising a nucleic acid in the form of an expression vector.